Intensive gastroscopy
Conditions
Interventions
phloroglucinol:Phloroglucinol 40 mg was injected intramuscularly
control group:2 ml normal saline was injected intramuscularly
Sponsors
The Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients were 20 years or older and required follow-up for confirmed or suspected upper GI disease. (2) Volunteered to participate in the clinical trial and signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) Previous surgery involving the upper GI tract, (2) severe gastric stenosis or deformation, (3) reflux esophagitis (Los Angeles classification B, C, or D), (4) active gastric or duodenal ulcer, and (5) receiving treatment for cancer (chemotherapy or radiotherapy). In addition, to ensure safety, the following exclusion criteria were also applied: (6) reduced cardiac function (New York Heart Association cardiac function classification grade III or higher), (7) upper GI bleeding requiring hemostasis, (8) a history of shock or hypersensitivity to phloroglucinol, and (9) women who were pregnant or nursing infants were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the antiperistaltic effect of phloroglucinol; | — |
Secondary
| Measure | Time frame |
|---|---|
| the impact of phloroglucinol on detection rate of gastric lesions;adverse drug reactions; | — |
Countries
China
Contacts
Public ContactChen Xia
The Affiliated Hospital of Southwest Medical University
Outcome results
None listed